Phospho-BTK (Tyr223/Tyr225) Antibody - #AF7354

Fig. 7| Enzastaurin and ibrutinib have synergistic antitumor effects in a DLBCL models in vivo. NPG mice subcutaneously inoculated with HBL-1(5 × 106) cells were randomized in four groups, respectively, treated as follow: enzastaurin (orally, 125 mg/kg, BID), ibtutinib (orally, 12 mg/kg, BID),combination of enzastaurin plus ibtutinib and control vehicle (n = 8 per group).e-f Immunohistochemistry assay of Ki-67, p-BTK and p-PKCβ protein expression in xenograft tumors. e Representative pictures of immunohistochemistry staining in sections are shown (Scale bar 60 μM).

Fig. 1 Expression of CD68 and BTK in renal tissues (× 400). a The single and double staining of CD68 and BTK in peritumoral normal renal tissues and IgAN renal tissues. b The count of single staining CD68 and BTK in glomeruli and tubulointerstitium (****p < 0.0001). c The count of double staining for CD68 and BTK in glomeruli and tubulointerstitium (****p < 0.0001)

Figure 5. Zanubrutinib inhibits phosphorylation of BTK and NF-κB in the IIM-ILD model. (a) Expression of changes in fibrosis-related indexes, including α-SMA, FN, COL1, and BTK, as well as NF-κB and their phosphorylation-related proteins, were analyzed by western blotting; (b、c、d、e、f) Statistical values are expressed as mean ±SD. *:p＜0.05; **:p＜0.01.